<DOC>
	<DOCNO>NCT01440933</DOCNO>
	<brief_summary>Sugammadex new reversal agent neuromuscular blocker ( curare ) . It encapsulate curare molecule terminates immediately action . The recommend dose 2 mg/kg slight neuromuscular block 4 mg/kg profound neuromuscular block . Magnesium sulphate frequently use perioperative medicine know reinforce neuromuscular block induce instance rocuronium . The researcher want investigate , whether high dos sugammadex must give antagonize neuromuscular block induce rocuronium patient receive magnesium sulphate .</brief_summary>
	<brief_title>Efficacy Sugammadex Magnesium Pretreated Patients</brief_title>
	<detailed_description>Neuromuscular block agent ( NMBAs ) frequently use anaesthesia intensive care medicine tracheal intubation , artificial ventilation , continue muscle relaxation surgical intervention . Postoperative residual curarisation associate increase risk postoperative complication morbidity . Consequently , adequate reversal neuromuscular block surgery great importance . Cholinesterase inhibitor widely use reversal agent . They increase amount acetycholine neuromuscular junction , compete NMBA restore muscle function . Cholinesterase inhibitor , however , number limitation . They antagonise neuromuscular block slowly effective partial spontaneous recovery already occur . These agent also associate relatively high incidence cholinergic adverse reaction , include bradycardia , arrhythmia , salivation , bronchoconstriction . Sugammadex , modify gamma cyclodextrin , selective binding agent specifically design encapsulate steroidal NMBAs rocuronium . It cause rapid complete reversal neuromuscular blockade prevent directly rocuronium react neuromuscular receptor . Dose-finding study suggest sugammadex 2 mg kg-1 need reversal moderate neuromuscular block ( reappearance T2 ) , dose ≥4 mg kg-1 need reversal profound block ( 1 2 post-tetanic count ) . The median time recovery moderate neuromuscular block T4/T1 ratio 0.9 ( consider clinically safe ) around two minute , profound neuromuscular block three minute . Magnesium sometimes use perioperative medicine , instance , prevent seizure parturients pre-eclampsia . Magnesium impact neuromuscular transmission . It reduce amount acetylcholine release motor nerve terminal , decrease calcium conductance presynaptic voltage-dependent calcium channel . After pre-treatment clinically relevant dose magnesium sulphate ( MgSO4 ) , increase speed onset prolongation recovery period neuromuscular blockade observe standard intubation dose atracurium , vecuronium , rocuronium . With rocuronium , instance , investigator record shorten speed onset neuromuscular block 35 % expense prolongation recovery period 25 % . It show interaction magnesium rocuronium may become relevant specific clinical situation . The clinically relevant interaction MgSO4 rocuronium beg question whether patient receive MgSO4 , efficacy sugammadex reverse rocuronium-induced block may affect . Indeed , animal study indicate significantly high dos sugammadex might need reverse rocuronium-induced neuromuscular block magnesium pretreatment . The aim study test hypothesis establish dose sugammadex fast safe reversal moderate profound rocuronium-induced neuromuscular block inadequate patient receive MgSO4 . The investigator hypothesize subject receive magnesium pretreatment , time reverse moderate deep neuromuscular block ( induce single intubation dose rocuronium ) standard dose sugammadex ( 2 4 mg kg-1 , respectively ) prolong ≥ 50 % dose response curve displace right ( i.e . high dose sugammedex necessary achieve speed action patient expose magnesium .</detailed_description>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>Age ≥18 60 year , male . American Society Anesthesiology [ ASA ] status I II . Able read understand information sheet sign date consent form . Scheduled elective surgery last least 60 minute general anaesthesia require neuromuscular relaxation use rocuronium bromide endotracheal intubation . A history allergy hypersensitivity rocuronium , sugammadex magnesium Neuromuscular disease . Preoperative medication know influence neuromuscular function ( instance , certain antibiotic [ aminoglycosides ] anticonvulsant [ phenytoine ] ) . Electrolyte abnormality ( instance , hypermagnaesemia ) . Hepatic dysfunction ( i.e bilirubin &lt; 1.5 upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) &lt; 2.5 x ULN , aspartate aminotransferase ( AST ) &lt; 2.5 x ULN ) Renal insufficiency ( i.e . Creatinine &lt; 1.5 x ULN , creatinine clearance &lt; 30ml/minute ) . Atrioventricular heart block Patients magnesium treatment Patients body mass index &lt; 19 &gt; 28 kg m2 . Pregnant , intend become pregnant , woman . Breastfeeding woman . Expected difficult intubation mask ventilation . Patient participate clinical trial within 30 day , inclusive , sign informed consent form current trial . Patients need continuous repeat rocuronium administration surgical reason .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>sugammadex</keyword>
	<keyword>rocuronium</keyword>
	<keyword>magnesiumsulphate</keyword>
	<keyword>neuromuscular monitoring</keyword>
</DOC>